In Vitro Diagnostics Market Size to Hit USD 190 billion by 2035 | Exclusive Report by Roots Analysis

The In Vitro Diagnostics Market size was valued at USD 108 billion in 2024 and likely to hit over USD 190 billion by 2035, growing at a CAGR of 5.2% during the forecast period 2024 to 2035

In vitro diagnostics (IVD) are the tests conducted on samples retrieved from human body, such as blood, saliva or tissue in order to detect diseases or conditions. Such tests help diagnose, monitor, and manage diseases, such as diabetes, infectious diseases, and cancer. The common types of IVD tests include immunoassays, molecular diagnostics, and clinical chemistry tests. Such tests play a crucial role in healthcare by providing timely and accurate information for medical decision-making. IVD solutions are essential tools for screening, diagnosing, and monitoring diseases, ultimately contributing to improved patient outcomes and public health.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/in-vitro-diagnostics-market/request-quote.html

By test type, the laboratory testing segment is expected to account for the largest share of the global In Vitro Diagnostics Market
It is worth mentioning that the point-of-care testing segment is expected to grow at a higher CAGR compared to laboratory testing market owing to their ability to deliver rapid test results and offer improved convenience and accessibility.

By type of offering, reagents hold a significant market share during the forecast period
The large share of reagents in the in vitro diagnostics market is likely due to the fact that the reagents are required to be replenished frequently, thus generating a recurring stream of revenue for the companies.

By type of technology, immunoassay segment led the global In Vitro Diagnostics Market
The immunoassay segment occupies the highest share (34%) in 2024 and is expected to witness substantial growth during the forecast period. This is followed by clinical chemistry segment which occupies the second largest IVD market share.

By therapeutic areas, infectious disease segment is anticipated to capture the largest share of the global in vitro diagnostics market
The market growth of the in vitro diagnostics market is expected to be driven by the increasing prevalence of chronic disorders, leading to a CAGR of 5.2% over the forecast period. Further, in terms of therapeutic areas, in vitro diagnostic solutions intended for infectious diseases currently capture the majority (41%) of the market share.

By end users, hospitals segment is anticipated to capture the largest share of the global in vitro diagnostics market
Hospitals are expected to hold the majority IVD market share (48%) in 2024 and this trend is expected to continue till 2035, whereas the laboratories segment is expected to grow at the highest growth rate of 5.5%, compared to other segments.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/in-vitro-diagnostics-market/request-sample.html

In Vitro Diagnostics Market - Regional Analysis
North America is expected to dominate the in vitro diagnostics market. In recent years, technological advancements have resulted in a tremendous increase in the adoption of in vitro diagnostic solutions across various healthcare settings. This indicates that North America plays a significant role in the global in vitro diagnostics market and showcases the need for companies to focus on this region in order to capitalize on the growing demand for in vitro diagnostic solutions.
Asia is a key region for the in vitro diagnostics market, with countries like China, Japan, South Korea, and India playing a central role. It is worth highlighting that, in the coming years, owing to the anticipated increase in the demand for in vitro diagnostic solutions, the market in Asia is likely to grow at a healthy CAGR during the forecast period.

Key Market Players
1. Abbott Laboratories
2. Agilent Technologies
3. Becton Dickinson
4. bioMérieux
5. Bio-Rad
6. Danaher Corporation
7. DiaSorin
8. Exact Sciences
9. Fujifilm
10. Gold Standard Diagnostics
11. Grifols
12. Hologic
13. Illumina
14. LabCorp
15. Qiagen
16. Quest Diagnostics
17. QuidelOrtho
18. Roche
19. Siemens Healthineers
20. Sysmex
21. Thermo Fisher Scientific
22. Werfen

In Vitro Diagnostics Market - Key Segments
In Vitro Diagnostics Market, by Test Type
1. Laboratory Testing
2. Point-of-Care Testing

In Vitro Diagnostics Market, by Type of Offering
1. Reagents
2. Instruments
3. Services

In Vitro Diagnostics Market, by Type of Technology
1. Clinical Chemistry
2. Hematology
3. Immunoassay
4. Molecular Diagnostics
5. Others

In Vitro Diagnostics Market, by Therapeutic Area
1. Autoimmune Diseases
2. Cardiovascular Disorders
3. Diabetes
4. Infectious Diseases
5. Renal Disorders
6. Oncological Disorders
7. Others

In Vitro Diagnostics Market, by End Users
1. Hospitals
2. Laboratories
3. Others

In Vitro Diagnostics Market, by Geographical Regions
1. North America
2. Europe
3. Asia
4. Latin America
5. Middle East and North Africa
6. Rest of the World

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/in-vitro-diagnostics-market.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.